Pharmaceutical Preparations · NYSE
For the period ended December 31, 2025, ABBOTT LABORATORIES reported $44.3 billion across 4 reportable segments: Medical Devices ($21.39B, 48.3%), Diagnostic Products ($8.94B, 20.2%), Nutritional Products ($8.45B, 19.1%), Established Pharmaceuticals ($5.54B, 12.5%). Medical Devices's share of the total is up from 38.4% for the period ended December 31, 2019.
For the period ended December 31, 2025, ABBOTT LABORATORIES reported $44.3 billion across 8 geographies: United States ($17.13B, 38.6%), All Other ($15.98B, 36.0%), Germany ($2.76B, 6.2%), China ($1.91B, 4.3%), and 4 smaller geographies. United States's share of the total is up from 37.6% for the period ended December 31, 2020.
ABBOTT LABORATORIES annual revenue by reportable segment, as disclosed in SEC filings.
| Segment | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | Share |
|---|---|---|---|---|---|---|
| Medical Devices | $14.48B | $14.80B | $16.89B | $18.99B | $21.39B | 48.3% |
| Diagnostic Products | $15.53B | $16.47B | $9.99B | $9.34B | $8.94B | 20.2% |
| Nutritional Products | $8.29B | $7.46B | $8.15B | $8.41B | $8.45B | 19.1% |
| Established Pharmaceuticals | $4.72B | $4.91B | $5.07B | $5.19B | $5.54B | 12.5% |
| Total | $43.02B | $43.64B | $40.09B | $41.93B | $44.31B |
ABBOTT LABORATORIES annual revenue by geography, as disclosed in SEC filings.
| Region | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | Share |
|---|---|---|---|---|---|---|
| International | — | — | $24.66B | $25.63B | — | — |
| United States | $16.64B | $18.14B | $15.45B | $16.32B | $17.13B | 38.6% |
| All Other | $15.73B | $15.01B | — | — | $15.98B | 36.0% |
| Germany | $2.57B | $2.34B | — | — | $2.76B | 6.2% |
| China | $2.39B | $2.13B | — | — | $1.91B | 4.3% |
| Switzerland | $1.31B | $1.34B | — | — | $1.87B | 4.2% |
| India | $1.56B | $1.65B | — | — | $1.87B | 4.2% |
| Japan | $1.70B | $1.93B | — | — | $1.48B | 3.3% |
| United Kingdom | — | — | — | — | $1.34B | 3.0% |
| Netherlands | $1.17B | $1.11B | — | — | — | — |
| Total | $43.08B | $43.65B | $40.11B | $41.95B | $44.33B |
Extracted from the XBRL segment tags in the company’s SEC filings. Figures are as reported and are not restated or adjusted.
Data: SEC EDGAR (financials, KPIs, segments) · Yahoo Finance (price, splits, metrics, analyst estimates, news headlines). Not financial advice.